BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 23394379)

  • 1. Vedolizumab for Crohn's disease.
    Mosli MH; Feagan BG
    Expert Opin Biol Ther; 2013 Mar; 13(3):455-63. PubMed ID: 23394379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
    Sands BE; Feagan BG; Rutgeerts P; Colombel JF; Sandborn WJ; Sy R; D'Haens G; Ben-Horin S; Xu J; Rosario M; Fox I; Parikh A; Milch C; Hanauer S
    Gastroenterology; 2014 Sep; 147(3):618-627.e3. PubMed ID: 24859203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
    Hagan M; Cross RK
    Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
    Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
    Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vedolizumab in the treatment of Crohn's disease.
    Tarabar D; Hirsch A; Rubin DT
    Expert Rev Gastroenterol Hepatol; 2016; 10(3):283-90. PubMed ID: 26810276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
    Lam MC; Bressler B
    Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.
    McLean LP; Cross RK
    Expert Opin Investig Drugs; 2016; 25(3):263-73. PubMed ID: 26822204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
    McLean LP; Cross RK
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit-Risk Assessment of Vedolizumab in the Treatment of Crohn's Disease and Ulcerative Colitis.
    Battat R; Ma C; Jairath V; Khanna R; Feagan BG
    Drug Saf; 2019 May; 42(5):617-632. PubMed ID: 30830573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vedolizumab as a rescue therapy for patients with medically refractory Crohn's disease.
    Crowell KT; Tinsley A; Williams ED; Coates MD; Bobb A; Koltun WA; Messaris E
    Colorectal Dis; 2018 Oct; 20(10):905-912. PubMed ID: 29673053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.
    Scribano ML
    World J Gastroenterol; 2018 Jun; 24(23):2457-2467. PubMed ID: 29930467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vedolizumab in the treatment of Crohn's disease].
    Gisbert JP; Domènech E
    Gastroenterol Hepatol; 2015 May; 38(5):338-48. PubMed ID: 25619903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials.
    Feagan BG; Bhayat F; Khalid M; Blake A; Travis SPL
    J Crohns Colitis; 2018 Jul; 12(8):905-919. PubMed ID: 29788248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease.
    Yamada A; Komaki Y; Patel N; Komaki F; Pekow J; Dalal S; Cohen RD; Cannon L; Umanskiy K; Smith R; Hurst R; Hyman N; Rubin DT; Sakuraba A
    Inflamm Bowel Dis; 2018 Feb; 24(3):502-509. PubMed ID: 29462385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teduglutide in Crohn's disease.
    Blonski W; Buchner AM; Aberra F; Lichtenstein G
    Expert Opin Biol Ther; 2013 Aug; 13(8):1207-14. PubMed ID: 23834252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etrolizumab for ulcerative colitis: the new kid on the block?
    Makker J; Hommes DW
    Expert Opin Biol Ther; 2016; 16(4):567-72. PubMed ID: 26914639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review and expert opinion of the use of certolizumab for Crohn's disease.
    Evans AT; Lee SD
    Expert Opin Biol Ther; 2012 Mar; 12(3):363-70. PubMed ID: 22339409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of vedolizumab for the treatment of ulcerative colitis.
    Novak G; Hindryckx P; Khanna R; Jairath V; Feagan BG
    Expert Opin Drug Saf; 2017 Apr; 16(4):501-507. PubMed ID: 28276855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.
    Garnock-Jones KP
    BioDrugs; 2015 Feb; 29(1):57-67. PubMed ID: 25502899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab.
    Hinojosa Del Val J; Barreiro-de Acosta M
    Gastroenterol Hepatol; 2019 Dec; 42(10):650-656. PubMed ID: 31635855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.